Press release Biocartis Group NV

Biocartis announces planned operational reorganization and cost reduction program

PRESS RELEASE                        

REGULATED INFORMATION – INSIDE INFORMATION

15 June 2023, 17:15 CEST

BIOCARTIS ANNOUNCES PLANNED OPERATIONAL REORGANIZATION AND COST REDUCTION PROGRAM

• Focusing investments on near-term product revenue generation and strategic partnerships that are expected to drive sustainable growth
• Approximately EUR 18 million of annualized cost reductions
• Cost reductions across the organization to create a clear path to break-even EBITDA¹ by the end of 2024
• Have engaged in constructive dialogue with key creditors and planning to engage an international investment bank to assist in developing a recapitalization plan for the Company

Mechelen, Belgium, 15 June 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces a planned reorganization and cost reduction program. The plan projects to reduce operating expenses by an annualized EUR 18 million, and is expected to lead to break-even EBITDA by the end of 2024. The Company plans to focus its investments on profitable revenue generation and strategic partnerships that are expected to drive sustainable growth and shareholder value. The plan aims at creating a self-sustaining business as a basis for a recapitalization that would secure the Company’s remaining funding needs and enable value appreciation for all stakeholders.

This planned reorganization enables a shift towards profitability through an increased focus on partner funded test menu expansion and a more targeted US commercial strategy to increase oncology test utilization.

Commenting on the planned reorganization, Roger Moody, Chief Executive Officer of Biocartis, said: “This reorganization is the first step necessary to create a clear path to financial independence by focusing on near-term growth from our existing business and delivering on our strategic partnership agreements that provide long-term value. I am confident that the streamlined organization will be able to continue to build on the strengths of our fully automated molecular platform with its unmatched ease-of-use, turn-around-time and sample versatility in oncology. We are fortunate to have and we fully support our trusted partnerships that include objectives to expand the number of tests that deliver fast and accurate results to cancer patients with currently unmet needs. Turning to our next steps, I look forward to working with our investors to secure the funds needed to achieve break-even EBITDA and recapitalize the balance sheet to clear the way for meaningful shareholder value creation.”